NASDAQ · OCS
Oculis Holding AG
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OCS: Nov 9, 2026
Oculis Holding AG Ordinary shares is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.49. The reported EPS for the same quarter last year was $-0.4.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.49 | $-0.46 | $-0.52 | 4 |
| Dec 2026 | $-0.50 | $-0.47 | $-0.53 | 3 |
| Mar 2027 | $-0.47 | $-0.47 | $-0.47 | 2 |
| Jun 2027 | $-0.46 | $-0.45 | $-0.47 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- RTTNews · Oct 22, 3:13 AM EDTOculis Reports New Phase 2 Privosegtor Biomarker Findings In Optic Neuritis(RTTNews) – Oculis Holding AG (OCS) said Thursday new biomarker analyses from its Phase 2 ACUITY trial showed that privosegtor reduced increases in blood markers of nerve injury and inflammation compared with placebo in patients with optic neuritis.
- RTTNews · Oct 20, 4:12 AM EDTOculis To Present Additional Phase 2 ACUITY Biomarker Data For Privosegtor In Optic Neuritis(RTTNews) – Oculis Holding AG (OCS) announced that it will present new biomarker analyses from the Phase 2 ACUITY trial of Privosegtor in patients with acute optic neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting, scheduled for October 21-23, 2026, in Toronto, Canada. The prese
- Zacks · Sep 28, 8:35 AM EDTAfter Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)Oculis Holding AG (OCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near te
- Zacks · Sep 23, 5:30 AM EDTStrength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- Zacks · Aug 31, 9:55 AM EDTWall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to TradeThe mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- RTTNews · Aug 24, 6:15 AM EDTOculis Treats First Patient In PIONEER-1 Trial Of Privosegtor In Optic Neuritis; Stock Up(RTTNews) – Oculis Holding AG(OCS), a biopharmaceutical company, announced that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of Optic Neuritis or ON.
- RTTNews · Aug 15, 2:59 AM EDTWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals(RTTNews) – This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts.
- Zacks · Aug 14, 9:55 AM EDTDoes Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Aug 6, 10:35 PM EDTOculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue EstimatesOculis Holding AG (OCS) delivered earnings and revenue surprises of +58.33% and +49.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 3, 5:20 PM EDTVertex Pharmaceuticals (VRTX) Q2 Earnings Lag EstimatesVertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 3, 5:16 AM EDTOculis Announces Supportive FDA Pre-IND Feedback For Privosegtor In Multiple Sclerosis; Stock Up(RTTNews) – Oculis Holding AG(OCS) announced positive U.S. Food and Drug Administration (FDA) pre-Investigational New Drug (IND) feedback regarding Privosegtor's clinical development plan in acute multiple sclerosis (MS) relapses.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Oculis Holding AG from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.